Durham’s Bioventus Finalizes Misonix Acquisition Expanding Firm’s Global Commercial Reach
Durham-based Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, finalized its acquisition of Misonix making the New York-based provider of minimally invasive therapeutic ultrasound technologies and regenerative medicine a wholly owned subsidiary of the company. According to Ken Reali, CEO, Bioventus, “The commercial reach of the new Bioventus is significantly broader, deeper and even more global. The acquisition has significant revenue growth opportunities via sales call point synergies that we share with Misonix, including spinal and lower extremity surgeons.”
The company also expects the merger to speed the adoption of its newly launched platform to facilitate ultrasonic procedures across spinal decompressions using its cranial tumor ablation device as well as its device for tissue debridement in chronic wounds. Mr. Reali continued, “The combination with Misonix Bioventus allows us to go deeper with our customer base, leveraging our infrastructure and benefiting patients, physicians, surgeons, as well as our more than 1,200 employees worldwide.”
Bioventus noted in a recent press release that the acquisition is aligned with the company’s mission of “delivering innovations for active healing to patients and providers.” The company also gave a nod to the deal’s role in progressing its revenue growth strategy and robust sales force focused on surgical applications in spinal fusion, neurosurgery of the cranium and wound treatments.
According to Bioventus, the combined organization anticipates delivering consistent double-digit revenue growth by supporting a total addressable market in the $15B range. Bioventus anticipates this growth will stem from its ability to gain substantial market share in multiple surgical applications including wound healing. As of the closing of the transaction, Stavros Vizirgianakis and Patrick Beyer, former members of Misonix’s Board of Directors, have joined the Bioventus Board of Directors.